

# Contents

## Section 1 Introduction to Natural Products for Drug Discovery

### Chapter 1 Natural Products as Drugs and Leads to Drugs: The Historical Perspective

*David J. Newman and Gordon M. Cragg*

1	Ancient History (>2900 BCE to 1800 CE)	3
2	The Initial Influence of Chemistry upon Drug Discovery	6
2.1	Alkaloids	6
2.2	Aspirin	8
2.3	Digitalis	9
3	20th and 21st Century Drugs/Leads from Nature	10
3.1	Antibacterial and Antifungal Antibiotics	10
3.2	Antiviral Agents	19
3.3	Natural Product Based Antitumour Agents	21
4	Final Comments	23
	References	24

### Chapter 2 Chemical Space and the Difference Between Natural Products and Synthetics

*Sheo B. Singh and J. Chris Culbertson*

1	Introduction	28
2	Sources of Organic Compounds and Drug Leads	29
2.1	Natural Products	29
2.2	Natural Product Derivatives	29
3	Synthetic Compounds	30
3.1	Synthetic Compound Libraries	30
3.2	Combinatorial Libraries	30

---

RSC Biomolecular Sciences No. 18  
Natural Product Chemistry for Drug Discovery  
Edited by Antony D. Buss and Mark S. Butler  
© Royal Society of Chemistry 2010  
Published by the Royal Society of Chemistry, www.rsc.org

3.3	Diversity-Oriented Synthetic (DOS) Libraries	31
3.4	Fragment Libraries	31
4	Lipinski's "Rule of Five" for Orally Active Drugs	32
5	Assessment of Diversity of Libraries with Respect to Drugs	33
5.1	Molecular Weight	34
5.2	Distribution of Atom Types: H-bond Donors and Acceptors	35
5.3	Lipophilicities (Log P)	37
5.4	Chiral Centres	37
5.5	Rotatable Bonds, Unsaturation, Rings, Chains and Ring Topology	38
6	Principal Component Analysis (PCA)	39
7	Conclusions	40
	References	42

### Chapter 3 Mechanism of Action Studies

*James J. La Clair*

1	Introduction	44
2	Some Like It Hot: Esperamicin A <sub>1</sub> , Neocarzinostatin and Related Eneidyne Antibiotics	45
3	To Catch a Mockingbird: Taxol, Epothilone and the Microtubule	47
4	Notorious: Jaspalakinolide, Alias Jaspamide and Actin	51
5	Invasion of the Pathway Snatchers: Artemisinin	53
6	Once Upon a Time in the Immune System: FK-506, Cyclosporin A and Rapamycin	55
7	Back to the Cytoskeleton: the Phorbolazoles	56
8	It's a Wonderful Target: VTPase and its Targeting by Apicularen A, Salicylhalamide A and Palmerolide A	59
9	Double Indemnity: Bistramide A	61
10	The Matrix: the Pladienolides and Splicing Factor SF3b	62
11	The Unusual Suspects: (+)-Avrainvillamide	65
12	Close Encounters of a Third Kind: Ammosamides, Blebbistatin and Myosin	67
13	The End	69
	References	69

## Section 2 Sources of Compounds

**Chapter 4 The Convention on Biological Diversity and its Impact on Natural Product Research***Geoffrey A. Cordell*

1	Introduction	81
2	Historical Perspective	85
3	The Convention on Biological Diversity	87
4	Implementation and Regulatory Outcomes of the CBD	92
5	Assessment of Impact	95
	5.1 An Overview and Some Examples	95
	5.2 An Informal Survey	100
	5.3 Survey Results	101
	5.4 Survey Overview	116
6	The TRIPS Agreement and the CBD	116
7	Other Aspects and Outcomes	123
	7.1 The International Cooperative Biodiversity Group Programme	125
8	Some Recommendations	127
9	A Web of Interconnectedness	130
10	A Different World	131
11	Conclusions	133
	Acknowledgements	134
	References	135

**Chapter 5 Plants: Revamping the Oldest Source of Medicines with Modern Science***Giovanni Appendino and Federica Pollastro*

1	Introduction	140
2	Plant Secondary Metabolites vs. Secondary Metabolites of Other Origin	143
3	Unnatural Sources of Plant Secondary Metabolites	146
4	Critical Issues in Plant-based Natural Product Drug Discovery	149
	4.1 Intellectual Property (IP) Issues	149
	4.2 Pleiotropy and Synergy	151
	4.3 Extract Libraries vs. Fraction (Peak) Libraries vs. Compound Libraries	153
	4.4 Removal of Interfering Compounds	155
5	Selection Strategies for Plant-Based Natural Product Drug Discovery	156
	5.1 Ethnopharmacology	156

5.2	Zoopharmacy and Animal Toxicology	157
5.3	Traditional Medicine	158
5.4	Dietary Plants and Spices	159
6	The Pharmaceutical Relevance of Plants	161
6.1	Plants as a Source of Lead Structures and Drugs	161
6.2	Plants as a Source of Standardised Extracts	163
7	Conclusions	167
	References	168

**Chapter 6 Macromarines: A Selective Account of the Potential of Marine Sponges, Molluscs, Soft Corals and Tunicates as a Source of Therapeutically Important Molecular Structures**

*Jennifer Carroll and Phillip Crews*

1	Introduction	174
1.1	Macroorganisms: Outstanding Success in Producing Viable Drug Leads	175
1.2	Setting that Ara A and Ara C Story Straight	175
1.3	The Potential Role of Invertebrate Associated Microorganisms and Secondary Metabolite Production	176
1.4	Macromarine Evolution	176
2	Sponges	177
2.1	Natural History of Sponges—a Primitive Phylum with Remarkable Biosynthetic Capabilities	177
3	Molluscs	186
3.1	Natural History of Molluscs—the Source of Numerous Preclinical Drug Leads	186
4	Soft Corals	189
4.1	Natural History of Cnidarians—the “Stinging Nettle” of the Sea	189
5	Tunicates	192
5.1	Natural History of Tunicates—Our Closest Marine Invertebrate Relations	192
6	Conclusions	194
	References	195

**Chapter 7 Microorganisms: Their Role in the Discovery and Development of Medicines**

*Cedric Pearce, Peter Eckard, Iris Gruen-Wollny and Friedrich G. Hansske*

1	Introduction	215
2	Bacteria	218
3	Fungi	220
4	Terrestrial and Marine Microorganisms	221

<i>Contents</i>	xiii
5 Microbial Culture Collections	222
6 Evidence for “Uncultivable” Microbes	223
7 Metagenomic Approach to Access Uncultivable Microbes	224
8 Culturing Techniques to Produce Secondary Metabolites	225
9 Evidence for New Biosynthetic Pathways in Known Microbes	227
10 Genetic Pathway Engineering and Modulation of Post-translational Modification to Generate Novel Compounds	227
11 Microbial Secondary Metabolites with Unique Biological Activity and Chemical Diversity	228
12 Microbial Secondary Metabolites with Unique Pharmacological Activity	231
13 Conclusions	232
Structures Discussed in Tables 7.2 and 7.3	233
References	236

### Section 3 Advances in Technology

#### Chapter 8 **Advances in Biological Screening for Lead Discovery** *Christian N. Parker, Johannes Ottl, Daniela Gabriel and Ji-Hu Zhang*

1 Introduction	245
1.1 Natural Product Screening and the Development of HTS	247
1.2 Chapter Objectives	247
2 Types of HTS Assays	247
2.1 <i>In vitro</i> Biochemical Assays	248
2.2 Cell-based Assays	255
2.3 Modelling to Identify False Positives and Negatives	261
3 Emerging Trends	262
3.1 New HTS Approaches	262
Acknowledgements	265
References	265

#### Chapter 9 **Advances in Instrumentation, Automation, Dereplication and Prefractionation** *Tim S. Bugni, Mary Kay Harper, Malcolm W.B. McCulloch and Emily L. Whitson*

1 Introduction	272
2 Dereplication	274

3	Extraction	275
4	Prefractionation	276
5	Isolation and Purification	278
	5.1 Automated Purification	279
6	HPLC Separation Technologies	279
7	Mass Spectrometry	282
8	NMR	285
	8.1 Probe Technology	285
	8.2 Structure Elucidation	287
	8.3 Methods for Fast NMR	288
	8.4 Automated Structure Elucidation	290
	8.5 Configuration by NMR	291
	8.6 Residual Dipolar Couplings	292
9	Conclusions	292
	References	293

## **Chapter 10 Natural Product Combinatorial Biosynthesis: Promises and Realities**

*Daniel W. Udvary*

1	Introduction	299
2	A Brief History of Natural Product Biosynthesis	300
3	Promises	304
4	Realities	307
5	Future Biotechnological Promises	312
	References	314

### **Section 4 Natural Products in Clinical Development**

## **Chapter 11 A Snapshot of Natural Product-Derived Compounds in Late Stage Clinical Development at the End of 2008**

*Mark S. Butler*

1	Introduction	321
2	NP-derived Drugs Launched in the Last Five Years	324
3	Late Stage NDAs and Clinical Candidates	327
	3.1 Antibacterial	327
	3.2 Oncology	332
	3.3 Other Therapeutic Areas	340
4	Conclusions and Outlook	342
	References	343

**Chapter 12 From Natural Product to Clinical Trials: NPI-0052 (Salinosporamide A), a Marine Actinomycete-Derived Anticancer Agent**

*Kin S. Lam, G. Kenneth Lloyd, Saskia T. C. Neuteboom, Michael A. Palladino, Kobi M. Sethna, Matthew A. Spear and Barbara C. Potts*

1	Introduction	355
1.1	Bioprospecting Marine Actinomycetes and the Discovery of <i>Salinispora</i> and NPI-0052	355
1.2	The Ubiquitin–Proteasome System as a Target for Drug Development	356
2	Mechanism of Action	358
3	Microbiology of <i>Salinispora tropica</i> , Fermentation and Scale-up	359
4	Structural Biology and Structure–Activity Relationship Studies	361
5	Translational Biology	363
6	IND-Enabling Studies of NPI-0052	364
7	API Manufacturing	365
8	Formulation Development and Drug Product Manufacturing	366
9	Pharmacodynamics	367
10	Pharmacokinetics	368
11	Clinical Trials	368
12	Concluding Remarks	370
	Acknowledgements	370
	References	370

**Chapter 13 From Natural Product to Clinical Trials: Bevirimat, a Plant-Derived Anti-AIDS Drug**

*Keduo Qian, Theodore J. Nitz, Donglei Yu, Graham P. Allaway, Susan L. Morris-Natschke and Kuo-Hsiung Lee*

1	Introduction	374
2	Bioactivity-directed Fractionation and Isolation	375
3	Lead Identification	375
4	Lead Optimisation and SAR Study	377
4.1	Modification of the BA Triterpene Skeleton	377
4.2	Modification on C-3 Position of BA	378
4.3	Introduction of C-28 Side Chain into BA	382
4.4	Bifunctional BA Analogues—Potential for Maturation Inhibitor Development	383
5	Mechanism of Action Studies of Bevirimat	384

6	Preclinical Studies of Bevirimat	385
7	Clinical Trials and Current Status of Bevirimat	387
8	Conclusions	388
	Acknowledgements	388
	References	388

## Section 5 Case Studies of Marketed Natural Product-derived Drugs

### Chapter 14 Daptomycin

*Richard H. Baltz*

1	Introduction	395
2	Discovery of A21987C and Daptomycin	396
	2.1 Enzymatic Cleavage of the Fatty Acid Side Chain	396
	2.2 Chemical Modifications of the A21978C Core Peptide	397
3	Biosynthesis	397
	3.1 Analysis of the Daptomycin Biosynthetic Gene Cluster	397
	3.2 Daptomycin Structure	398
4	Mechanism of Action Studies	399
	4.1 Daptomycin Resistant Mutants	400
5	Antibacterial Activities	401
	5.1 <i>In vitro</i> Activities	401
	5.2 <i>In vivo</i> Activities in Animal Models	402
6	Clinical Studies	402
	6.1 Eli Lilly and Company	402
	6.2 The Passing of the Baton	403
	6.3 Cubist Pharmaceuticals	403
7	Lessons Learned	404
8	Epilogue	405
	References	405

### Chapter 15 Micafungin

*Akihiko Fujie, Shuichi Tawara and Seiji Hashimoto*

1	Introduction	410
	1.1 New Antifungal Compounds Discovered at Fujisawa (a Predecessor of Astellas Pharma Inc.)	411
	1.2 1,3- $\beta$ -Glucan Synthase Inhibition and Echinocandins	413
2	From the Discovery of FR901379 to Clinical Studies of FK463 (Micafungin)	414
	2.1 Discovery of FR901379	414
	2.2 Generation of Lead Compound FR131535	418



<i>Contents</i>	xvii
2.3 Lead Optimisation Leading to the Discovery of FK463 <sup>12,13</sup>	421
2.4 Preclinical Studies of FK463	425
2.5 Industrial Manufacturing of Micafungin	426
2.6 Clinical Studies of FK463	426
3 Conclusions	427
Acknowledgements	427
References	427
<b>Subject Index</b>	429

